Corporate Presentation
Developing the Next Generation of Targeted Therapies
Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT
Perspective’s Innovative Platform
Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window
Proposed Mechanism of Action for 212Pb
Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs
Perspective’s Pre-Targeting Platform
Supply Chain and Manufacturing Infrastructure
On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products
Neuroendocrine Tumors: VMT-⍺-NET
Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors
Anti-Tumor Activity
Signal of Sustained Anti-Tumor Activity
[212Pb]VMT-α-NET Was Well Tolerated
No Decline in Renal Function Observed
Patient with PR after [212Pb]VMT-α-NET
Melanoma Program: VMT01/02
Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma
Treatment Emergent Adverse Events (occurring in ≥ 2 patients and/or Grade ≥ 2)
PSV359 is Active Against FAP-α Expression on Tumor and on Stroma
General Corporate Information
Abbreviations